Literature DB >> 22178447

Stat1 and CD74 overexpression is co-dependent and linked to increased invasion and lymph node metastasis in triple-negative breast cancer.

Christina Greenwood1, Gergana Metodieva, Khalid Al-Janabi, Berthold Lausen, Louise Alldridge, Lin Leng, Richard Bucala, Nelson Fernandez, Metodi V Metodiev.   

Abstract

Triple-negative breast cancer is difficult to treat because of the lack of rationale-based therapies. There are no established markers and targets that can be used for stratification of patients and targeted therapy. Here we report the identification of novel molecular features, which appear to augment metastasis of triple negative breast tumors. We found that triple-negative breast tumors can be segregated into 2 phenotypes based on their genome-wide protein abundance profiles. The first is characterized by high expression of Stat1, Mx1, and CD74. Seven out of 9 tumors from this group had invaded at least 2 lymph nodes while only 1 out of 10 tumors in group 2 was lymph node positive. In vitro experiments showed that the interferon-induced increase in Stat1 abundance correlates with increased migration and invasion in cultured cells. When CD74 was overexpressed, it increased cell adhesion on matrigel. This effect was accompanied with a marked increase in the membrane expression of beta-catenin, MUC18, plexins, integrins, and other proteins involved in cell adhesion and cancer metastasis. Taken together, our results show that Stat1/CD74 positive triple-negative tumors are more aggressive and suggest an approach for development of better diagnostics and more targeted therapies for triple negative breast cancer. This article is part of a Special Issue entitled: Proteomics: The clinical link.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22178447     DOI: 10.1016/j.jprot.2011.11.033

Source DB:  PubMed          Journal:  J Proteomics        ISSN: 1874-3919            Impact factor:   4.044


  47 in total

1.  Cancer progression modeling using static sample data.

Authors:  Yijun Sun; Jin Yao; Norma J Nowak; Steve Goodison
Journal:  Genome Biol       Date:  2014-08-26       Impact factor: 13.583

2.  Unphosphorylated STAT1 promotes sarcoma development through repressing expression of Fas and bad and conferring apoptotic resistance.

Authors:  Mary A Zimmerman; Nur-Taz Rahman; Dafeng Yang; Guy Lahat; Alexander J Lazar; Raphael E Pollock; Dina Lev; Kebin Liu
Journal:  Cancer Res       Date:  2012-07-17       Impact factor: 12.701

3.  Identification of epigenetic modulators in human breast cancer by integrated analysis of DNA methylation and RNA-Seq data.

Authors:  Xin Zhou; Zhibin Chen; Xiaodong Cai
Journal:  Epigenetics       Date:  2018-08-07       Impact factor: 4.528

4.  Isorhapontigenin (ISO) Inhibits Invasive Bladder Cancer Formation In Vivo and Human Bladder Cancer Invasion In Vitro by Targeting STAT1/FOXO1 Axis.

Authors:  Guosong Jiang; Amy D Wu; Chao Huang; Jiayan Gu; Liping Zhang; Haishan Huang; Xin Liao; Jingxia Li; Dongyun Zhang; Xingruo Zeng; Honglei Jin; Haojie Huang; Chuanshu Huang
Journal:  Cancer Prev Res (Phila)       Date:  2016-04-14

5.  CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response.

Authors:  Abdul S Qadir; Paolo Ceppi; Sonia Brockway; Calvin Law; Liang Mu; Nikolai N Khodarev; Jung Kim; Jonathan C Zhao; William Putzbach; Andrea E Murmann; Zhuo Chen; Wenjing Chen; Xia Liu; Arthur R Salomon; Huiping Liu; Ralph R Weichselbaum; Jindan Yu; Marcus E Peter
Journal:  Cell Rep       Date:  2017-03-07       Impact factor: 9.423

6.  iTRAQ based quantitative proteomics approach validated the role of calcyclin binding protein (CacyBP) in promoting colorectal cancer metastasis.

Authors:  Dipanjana Ghosh; Zhihan Li; Xing Fei Tan; Teck Kwang Lim; Yubin Mao; Qingsong Lin
Journal:  Mol Cell Proteomics       Date:  2013-03-29       Impact factor: 5.911

7.  CD74: a potential novel target for triple-negative breast cancer.

Authors:  Buxian Tian; Yuhong Zhang; Nan Li; Xuewen Liu; Jianfeng Dong
Journal:  Tumour Biol       Date:  2012-08-31

8.  Lowly methylated region analysis identifies EBF1 as a potential epigenetic modifier in breast cancer.

Authors:  Nora Fernandez-Jimenez; Athena Sklias; Szilvia Ecsedi; Vincent Cahais; Davide Degli-Esposti; Antonin Jay; Pierre Benoit Ancey; Hae Dong Woo; Hector Hernandez-Vargas; Zdenko Herceg
Journal:  Epigenetics       Date:  2017-11-10       Impact factor: 4.528

9.  Quantitative proteome profiling of lymph node-positive vs. -negative colorectal carcinomas pinpoints MX1 as a marker for lymph node metastasis.

Authors:  Roland S Croner; Michael Stürzl; Tilman T Rau; Gergana Metodieva; Carol I Geppert; Elisabeth Naschberger; Berthold Lausen; Metodi V Metodiev
Journal:  Int J Cancer       Date:  2014-05-12       Impact factor: 7.396

10.  MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer.

Authors:  Suresh B Pakala; Suresh K Rayala; Rui-An Wang; Kazufumi Ohshiro; Prakriti Mudvari; Sirigiri Divijendra Natha Reddy; Yi Zheng; Ricardo Pires; Sandra Casimiro; M Radhakrishna Pillai; Luis Costa; Rakesh Kumar
Journal:  Cancer Res       Date:  2013-04-11       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.